PAI-2 inhibits the chemiluminescence of phagocytes and suppresses autoimmunity

Fibrinolysis and Proteolysis

Volumn 13, Issue 6, 1999, Pages 245-251

  Stief, T W ^a   Schorlemmer, H U ^b   Beck Speier, I ^c   Doss, M O ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b SANOFI   (France)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR;

ALLERGIC ENCEPHALITIS; ANIMAL MODEL; AUTOIMMUNITY; CHEMOLUMINESCENCE; DRUG EFFECT; DRUG USE; HUMAN; HUMAN CELL; MACROPHAGE ACTIVATION; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0033497944     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1054/fipr.1999.0038     Document Type: Article

References (57)

1. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365-376.
2. Cao D, Mizukami IF, Garni-Wagner BA, Kindzelskii AL, Todd III RF, Boxer LA, Petty HR. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible role for complement receptor type 3 and calcium. J Immunol 1995; 154: 1817-1829.
3. Witko V, Nguyen AT, Descamps-Latscha B. Microtiter plate assay for phagocyte derived taurine-chloramines. J Clin Lab Anal 1992; 6: 47-53.
4. Vogt W. Complement activation by myeloperoxidase products released from stimulated human polymorphonuclear leukocytes. Immunobiology 1996; 195: 334-346.
5. Bachmann F. The enigma PAI-2. Gene expression, evolutionary and functional aspects. Thromb Haemostas 1995; 74: 172-179.
6. Kruithof EKO, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86: 4007-4024.
7. Villarroya H, Marie Y, Ouallet JC, Le Saux F, Tchelingerian JL. Expression of TNF alpha in central neurons of Lewis rat spinal cord after EAE induction. J Neurosci Res 1997; 49: 592-599.
8. Schmidt S, Linington C, Zipp F, Sotgiu S, de Waal Malefyt R, Wekerle H, Hohlfeld R. Multiple sclerosis: comparison of the human T-cell response to S100 beta and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis. Brain 1997; 120: 1437-1445.
9. Dinter H, Onuffer J, Faulds D, Perez HD. Phosphodiesterase Type IV inhibitors in the treatment of multiple sclerosis. J Mol Med 1997; 75: 95-102.
10. Smith ME, van der Maesen K, Somera FP, Sobel RA. Effects of phorbol myristate (PMA) on functions of macrophages and microglia in vitro. Neurochem Res 1998; 23: 427-434.
11. Leonard JP, Waldburger KE, Schaub RG, Smith T, Hewson AK, Cuzner ML. Regulation of the inflammatory response in animal models of multiple sclerosis by interleukin-12. Crit Rev Immunol 1997; 17: 545-553.
12. Jacobs L, Goodkin DE, Rudick RA, Herndorn R. Advances in specific therapy for multiple sclerosis. Curr Opin Neurol 1994; 7: 250-254.
13. Stief TW, Lenz P, Becker U, Heimburger N. Determination of plasminogen activator inhibitor (PAI) capacity of human plasma in presence of oxidants: a novel principle. Thromb Res 1988; 50: 559-573.
14. Astedt B, Lecander I, Brodin I, Lundblad A, Löw K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemostas 1985; 53: 122-125.
15. Schorlemmer HU, Dickneite G. Preclinical studies with 15-deoxyspergualin in various animal models for autoimmune diseases. Annal New York Acad Sci 1993; 685: 155-174.
16. Schorlemmer HU, Bosslet K, Dickneite G, Lüben G, Sedlacek HH. Studies on the mechanism of action of the immunomodulator bestatin in various screening test systems. Behring Inst Res Commun 1984; 74: 157-173.
17. Schorlemmer HU, Bartlett RR. Malononitrilamides (MNA279 and MNA715) have therapeutic activity in acute and chronic relapsing experimental allergic encephalomyelitis (EAE). Inflamm Res 1997; 46 (suppl 2): S163-S164.
18. Stief TW, Stief MH, Ehrenthal W, Darius M, Martin E. Nonradical oxidants of the phagocyte type induce the activation of plasmatic single-chain urokinase. Thromb Res 1991; 63: 227-238.
19. Stief TW. Nonradical excited oxygen species induce selective thrombolysis in vivo. Thromb Res 1991; 62: 147-163.
20. Stief TW, Martin E, Caso F, Rodriguez JM. Oxidation susceptibility of plasminogen activator inhibitors of human plasma. Thromb Res 1990; 60: 177-180.
21. Babior BM. NADPH oxidase: an update. Blood 1999; 93: 1464-1476.
22. Lai L, Malik AB. Effect of tranexamic acid on neutrophil superoxide anion generation. Thromb Res 1986; 41: 269-274.
23. Webb AC, Collins KL, Snyder SE et al. Human monocyte Arg-Serpin cDNA. Sequence, chromosomal assignment, and homology to plasminogen activator-inhibitor. J Exp Med 1987; 166: 77-94.
24. Ye RD, Wun TC, Sadler JE. cDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta. J Biol Chem 1987; 262: 3718-3725.
25. Ny T, Mikus P. Plasminogen activator inhibitor type-2. A spontaneously polymerizing serpin that exists in two topological forms. Adv Exp Med Biol 1997; 425: 123-130.
26. Schuster MG, Enriquez PM, Curran P, Cooperman BS, Rubin H. Regulation of neutrophil superoxide by antichymotrypsin-chymotrypsin complexes. J Biol Chem 1992; 267: 5056-5059.
27. Matsushima K, Taguchi M, Kovacs RJ, Young HA, Oppenheim JJ. Intracellular localization of human monocyte associated interleukin 1 (IL 1) and release of biologically active IL 1 from monocytes by trypsin and plasmin. J Immunol 1986; 136: 2883-2891.
28. Goeken NE, Staggs TS, Ballas ZK. Monocyte suppressor factor is plasminogen activator inhibitor inhibition of membrane bound but not soluble IL-1. J Immunol 1989; 143: 603-608.
29. Robson SC, Saunders R, Kirsch RE. Monocyte-macrophage release of IL-1 is inhibited by type-1 plasminogen activator inhibitors. J Clin Lab Immunol 1990; 33: 83-90.
30. Durante W, Schini VB, Catovsky S, Kroll MH, Vanhoutte PM, Schafer AI. Plasmin potentiates induction of nitric oxide synthesis by interleukin-1 beta in vascular smooth muscle cells. Am J Physiol 1993; 264: H617-H624.
31. Wilson HM, Haites NE, Reid FJ, Booth NA. Interleukin-1 beta up-regulates the plasminogen/plasmin system in human mesangial cells. Kidney Int 1996; 49: 1097-1104.
32. Oleksyszyn J, Augustine AJ. Plasminogen modulation of IL-1-stimulated degradation in bovine and human articular cartilage explants. The role of the endogenous inhibitors: PAI-1, alpha 2-antiplasmin, alpha 1-PI, alpha 2-macroglobulin and TIMP. Inflamm Res 1996; 45: 464-472.
33. Hasegawa T, Sorensen L, Dohi M, Rao NV, Hoidal JR, Marshall BC. Induction of urokinase-type plasminogen activator receptor by IL-1 beta. Am J Respir Cell Mol Biol 1997; 16: 683-692.
34. Bednar M, Smith B, Pinto A, Mullane KM. Nafazatrom- induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function. Circ Res 1985; 57: 131-141.
35. Sibley WA, Kiernat J, Laguna JF. The modification of experimental allergic encephalomyelitis with epsilon amino caproic acid. Neurology 1978; 28: 102-108.
36. Brosnan CF, Cammer W, Norton WT, Bloom BR. Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis. Nature 1980; 285: 235-237.
37. Smith ME, Amaducci LA. Observations on the effects of protease inhibitors on the suppression of experimental allergic encephalomyelitis. Neurochem Res 1982; 7: 541-554.
38. Koh CS, Paterson PY. Suppression of clinical signs of cell-transferred experimental allergic encephalomyelitis and altered cerebrovascular permeability in Lewis rats treated with a plasminogen activator inhibitor. Cell Immunol 1987; 107: 52-63.
39. Genton C, Kruithof EKO, Schleuning WD. Phorbol ester induces the biosynthesis of glycosylated and non-glycosylated plasminogen activator inhibitor 2 in high excess over urokinase- type plasminogen activator in human U937 lymphoma cells. J Cell Biol 1987; 104, 705-712.
40. Bergonzelli GE, Kruithof EKO, Medcalf RL. Transcriptional antagonism of phorbol ester-mediated induction of plasminogen activator inhibitor types 1 and 2 by cyclic adenosine 3′,5′-monophosphate. Endocrinology 1992; 131: 1467-1472.
41. Smith T, Hewson AK, Kingsley CI, Leonard JP, Cuzner ML. Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol 1997; 150: 1909-1917.
42. Dear AE, Shen Y, Ruegg M, Medcalf RL. Molecular mechanisms governing tumor-necrosis factor-mediated regulation of plasminogen-activator inhibitor type-2 gene expression. Eur J Biochem 1996; 241: 93-100.
43. Stief TW. Oxidized fibrin stimulates the activation of pro-urokinase and is the preferential substrate of human plasmin. Blood Coagul Fibrinol 1993; 4: 117-122.
44. Dickinson JL, Bates EJ, Ferrante A, Antalis T. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor α-induced apoptosis. J Biol Chem 1995; 270: 27894-27900.
45. Brod SA, Marshall GD Jr, Henninger EM, Sriram S, Khan M, Wolinsky JS. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 1996; 46: 1633-1638.
46. Chambers SK, Ivins CM, Carcangiu ML. Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: a favourable prognostic factor related to the actions of CSF-1. Internat J Cancer 1997; 74: 571-575.
47. Schorlemmer HU, Kanzy EJ, Langner KD, Kurrle R. Immunomodulatory activity of recombinant IL-1 receptor (IL-1-R) on models of experimental rheumatoid arthritis. Agents and Actions 1993; 39: C113-C116.
48. Wiemann B, Van GY, Danilenko DM, Yan Q, Matheson C, Munyakazi L, Ogenstad S, Starnes CO. Combined treatment of acute EAE in Lewis rats with TNF binding protein and interleukin-1 receptor antagonist. Exp Neurol 1998; 149: 455-463.
49. Brosnan C, Bornstein MB, Bloom BR. The effects of macrophage depletion on the clinical and pathologic expression of experimental allergic encephalomyeliltis. Journal of Immunology 1981; 126: 614-620.
50. Indyk JA, Chen Z-L, Strickland S. Proteases and degradation of extracellular matrix in neurodegeneration. Fibrinolysis & Proteolysis 1999; 13: 64-71.
51. Nilsson IM, Felding P, Lecander I, Lenner C, Astedt B. Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women. Brit J Haematol 1986; 62: 215-220.
52. Kruithof EKO, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69: 460-466.
53. Estelles A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma level of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989; 74: 1332-1338.
54. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T, and the pregnancy in multiple sclerosis group. Rate of pregnancy - related relapse in multiple sclerosis. N Engl J Med 1998; 339: 285-291.
55. Lyons-Giordano B, Loskutoff D, Chen CS, Lazarus G, Keeton M, Jensen PJ. Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochemistry 1994; 101: 105-112.
56. Schaefer BM, Jaeger C, Drepper E, Kramer MD. Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis. Autoimmunity 1996; 23: 155-164.
57. Wallberg-Jonsson S, Rantapaa-Dahlqvist S, Nordmark L, Ranby M. Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondylarthropathy and their relation to radiological destruction. J Rheumatol 1996; 23: 1704-1709.